Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation

References

• Ameeduzzafar Ali J, Bhatnagar A, Kumar N, Ali A. 2014. Chitosan nanoparticles amplify the ocular hypotensive effect of cateolol in rabbits. Int J Biol Macromol. 65:479–491.
   PubMed Web of Science ®Google Scholar
• Amrite AC, Edelhauser HF, Kompella UB. 2008. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 49:320–322.
   PubMed Web of Science ®Google Scholar
• Badawi AA, El-Laithy HM, El-Qidra RK, El-Mofty H. 2008. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 31:1040–1049.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. 2007. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114:855–859.
   PubMed Web of Science ®Google Scholar
• Basaran E, Yazan Y. 2012. Ocular application of chitosan. Expert Opin Drug Deliv. 9:701–712.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. 2010. Diabetic retinopathy. Lancet. 376:124–136.
   PubMed Web of Science ®Google Scholar
• de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ. 2010. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev. 62:100–117.
   PubMed Web of Science ®Google Scholar
• de la Fuente M, Seijo B, Alonso MJ. 2008. Bioadhesive hyaluronan–chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther. 15:668–676.
   PubMed Web of Science ®Google Scholar
• del Amo EM, Urtti A. 2008. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today. 13:135–143.
   PubMed Web of Science ®Google Scholar
• Durán-Lobato M, Muñoz-Rubio I, Holgado M, Álvarez-Fuentes J, Fernández-Arévalo M, Martín-Banderas L. 2014. Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotech. 10:1068–1079.
   PubMed Web of Science ®Google Scholar
• Felt O, Carrel A, Baehni P, Buri P, Gurny R. 2000. Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy. J Ocul Pharmacol Ther. 16:261–270.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med. 9:669–676.
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. 2006. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 90:1344–1349.
   PubMed Web of Science ®Google Scholar
• Gambrelle J, Kodjikian L, Abi-Ayad N, Wolff B, Grange JD. 2006. Grange, persistent unsealed sclerotomy after intravitreal injection of triamcinolone acetonide with a 30-gauge needle. J Fr Ophtalmol. 29:e22.
   PubMedGoogle Scholar
• Gan Q, Wang T, Cochrane C, McCarron P. 2005. Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery. Colloids Surf B Biointerfaces. 44:65–73.
   PubMed Web of Science ®Google Scholar
• Gan Q, Wang T. 2007. Chitosan nanoparticle as protein delivery carrier—systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces. 59:24–34.
   PubMed Web of Science ®Google Scholar
• Guo C, Gemeinhart RA. 2008. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm. 70:597–604.
   PubMed Web of Science ®Google Scholar
• Hosoya KI, Lee VH, Kim KJ. 2005. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm. 60:227–240.
   PubMed Web of Science ®Google Scholar
• Huang D, Wang L, Dong Y, Pan X, Li G, Wu C. 2014. A novel technology using transscleral ultrasound to deliver protein loaded nanoparticles. Eur J Pharm Biopharm. 88:104–115.
   PubMed Web of Science ®Google Scholar
• ICCVAM. Appendix B3 of “ICCVAM test method evaluation report: current validation status of in vitro test methods proposed for identifying eye injury hazard potential of chemicals and products” NIH Publication, 2010. Available from: http://iccvam.niehs.nih.gov/methods/ocutox/MildMod-TMER.htm
   Google Scholar
• Jain GK, Pathan SA, Akhter S, Ahmad N, Jain N, Talegaonkar S, Khar RK, Ahmad FJ. 2010. Mechanistic study of hydrolytic erosion and drug release behaviour of PLGA nanoparticles: influence of chitosan. Polym Degrad Stab. 95:2360–2366.
   Web of Science ®Google Scholar
• Jain GK, Pathan SA, Akhter S, Jayabalan N, Talegaonkar S, Khar RK, Ahmad FJ. 2011. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces. 82:397–403.
   PubMed Web of Science ®Google Scholar
• Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M, Ali A, Sultana Y. 2014. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 102:117–124.
   PubMed Web of Science ®Google Scholar
• Kaur IP, Smitha R. 2002. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 28:353–369.
   PubMed Web of Science ®Google Scholar
• Kawashima T, Nagai N, Kaji H, Kumasaka N, Onami H, Ishikawa Y, et al. 2011. A scalable controlled-release device for transscleral drug delivery to the retina. Biomaterials. 32:1950–1956.
   PubMed Web of Science ®Google Scholar
• Kesavan K, Kant S, Singh PN, Pandit JK. 2012. Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Current Eye Res. 38:342–352.
   PubMed Web of Science ®Google Scholar
• Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG. 2004. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 45:2722–2731.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Jeong HO, Chung SK. 2010. The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol. 24:230–236.
   PubMedGoogle Scholar
• Lamoureux EL, Wong TY. 2011. Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials. Diabetes Care. 34:1066–1067.
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Pérez MH, Lehr CM, Hoffman M, Maincent P. 2000. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm. 196:177–182.
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhou N, Huang X, Cheng JW, Li FQ, Wei RL, Cai JP. 2014. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol. 7:1–7.
   PubMed Web of Science ®Google Scholar
• Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 290:137–144.
   PubMed Web of Science ®Google Scholar
• Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL. 2009. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials. 30:6541–6547.
   PubMed Web of Science ®Google Scholar
• Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M. 2010. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 51:1606–1608.
   PubMed Web of Science ®Google Scholar
• Molokhia SA, Sant H, Simonis J, Bishop CJ, Burr RM, Gale BK, Ambati BK. 2010. The capsule drug device: novel approach for drug delivery to the eye. Vision Res. 50:680–685.
   PubMed Web of Science ®Google Scholar
• Moon JW, Song YK, Jee JP, Kim CK, Choung HK, Hwang JM. 2006. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci. 47:3968–3974.
   PubMed Web of Science ®Google Scholar
• Myers RH, Montgomery DC. Response Surface Methodology Process and Product Optimization Using Designed Experiments. 2nd ed. New York: John Wiley & Sons, Inc.; 2002.
   Google Scholar
• Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. 2007. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 3:173–183.
   PubMed Web of Science ®Google Scholar
• Oh JY, Kim MK, Wee WR. 2009. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea. 28:1070–1073.
   PubMed Web of Science ®Google Scholar
• Pandit J, Sultana Y, Aqil M. 2014. Poly(lactide-co-glycolide) nanoparticles for an extended delivery of bevacizumab to retina: formulation and in vitro characterization. Adv Sci Lett. 20:1588–1593.
   Google Scholar
• Pascolini D, Mariotti SP. 2012. Global estimates of visual impairment: 2010. Br J Ophthalmol. 96:614–618.
   PubMed Web of Science ®Google Scholar
• Ranta VP, Mannermaa E, Lummepuro K, Subrizi A, Laukkanen A, Antopolsky M, et al. 2010. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 148:42–48.
   PubMed Web of Science ®Google Scholar
• Ranta VP, Urtti A. 2006. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 58:1164–1181.
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW, Jr, et al. 2006. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 26:495–511.
   PubMed Web of Science ®Google Scholar
• Shmueli RB, Ohnaka M, Miki A, Pandey NB, de Silva RL, Koskimaki JE, et al. 2013. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials. 34:7544–7551.
   PubMed Web of Science ®Google Scholar
• Simó R, Sundstrom JM, Antonetti DA. 2014. Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care. 37:893–899.
   PubMed Web of Science ®Google Scholar
• Son S, Lee WR, Joung YK, Kwon MH, Kim YS, Park KD. 2009. Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles. Int J Pharm. 368:178–185.
   PubMed Web of Science ®Google Scholar
• Srikantha N, Mourad F, Suhling K, Elsaid N, Levitt J, Chung PH, Jackson TL. 2012. Influence of molecular shape, conformability, net surface charge, and tissue interaction on transscleral macromolecular diffusion. Exp. Eye Res. 102:85–92.
   PubMed Web of Science ®Google Scholar
• Tavaszi J, Budai P. 2006. The use of HET-CAM test in detecting the ocular irritation. Commun Agric Appl Biol Sci. 72:137–141.
   Google Scholar
• Tyagi P, Barros M, Stansbury JW, Kompella UB. 2013. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 10:2858–2867.
   PubMed Web of Science ®Google Scholar
• van Wijngaarden P, Coster DJ, Williams KA. 2005. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 293:1509–1513.
   PubMed Web of Science ®Google Scholar
• Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, Esfahani MR, Dinarvand R. 2013. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci. 50:341–352.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li P, Kong L. 2013. Chitosan-modified PLGA nanoparticles with versatile surface for improved drug delivery. AAPS PharmSciTech. 14:585–592.
   PubMed Web of Science ®Google Scholar
• Watson PG, Young RD. 2004. Scleral structure, organisation and disease. A review. Exp Eye Res. 78:609–623.
   PubMed Web of Science ®Google Scholar
• Wen H, Hao J, Li SK. 2013. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. J Pharm Sci. 102:892–903.
   PubMed Web of Science ®Google Scholar
• Xu X, Weng Y, Xu L, Chen H. 2013. Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol. 60:272–276.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Vandervoort J, Ludwig A. 2009. Influence of chitosan layer on the properties of surface modified poly(lactide-co-glycolide) nanoparticles. J Disper Sci Technol. 30:213–216.
   Web of Science ®Google Scholar
• Yu J, Xu X, Yao F, Luo Z, Jin L, Xie B, et al. 2014. In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications. Int J Pharm. 470:151–157.
   PubMed Web of Science ®Google Scholar